Lanvis (Tioguanine)

Tioguanine is converted inside cells to thioguanine nucleotides, which become incorporated into DNA and RNA. This incorporation disrupts nucleic acid synthesis, impairs cell replication, and induces apoptosis in rapidly dividing malignant cells, while also inhibiting de novo purine synthesis.

The dose of Lanvis is individualized by the prescribing clinician based on the patient’s diagnosis, disease stage, body surface area, and laboratory parameters. Specific dosing regimens are not provided here and should follow the prescriber’s instructions.

Safety data for tioguanine in pregnancy and lactation are limited. Because the drug can affect rapidly dividing cells, it is generally avoided during pregnancy and breastfeeding unless the potential therapeutic benefit justifies the potential risk to the fetus or infant.

To order Lanvis, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lanvis (tioguanine) is chemically related to other purine analogs such as mercaptopurine and azathioprine. While all share a similar mechanism of interfering with nucleic acid synthesis, tioguanine has a distinct metabolic pathway and may be preferred in certain leukemia protocols due to its pharmacokinetic profile.

Lanvis should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product protected from moisture and direct light to maintain stability. Do not store in a refrigerator or freezer unless specifically instructed by the manufacturer.

Lanvis is administered orally. The tablets (or other oral form) are taken with a full glass of water, usually on an empty stomach or as directed by the treating physician. Swallow the dose whole; do not crush or chew unless advised otherwise.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, hepatic veno‑occlusive disease, life‑threatening infections due to immunosuppression, and the potential for secondary malignancies. Patients should be monitored closely for signs of these complications.

Lanvis should not be used in patients with known hypersensitivity to tioguanine or any component of the formulation, in those with severe hepatic or renal impairment without dose adjustment, and in pregnant or breastfeeding women unless the benefits outweigh the risks.